Dianthus Therapeutics Inc

DNTH

50.750USD

+4.170+8.95%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Dianthus Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

26 / 392

Overall Ranking

121 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Dianthus Therapeutics Inc Highlights

StrengthsRisks

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Growing

The company is in a growing phase, with the latest annual income totaling USD 6.24M.

Undervalued

The company’s latest PE is -14.49, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 46.28M shares, decreasing 2.31% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 15.00 shares of this stock.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

74.500

Target Price

+59.94%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Dianthus Therapeutics Inc is 5.96, ranking 308 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 396.00K, representing a year-over-year decrease of 81.77%, while its net profit experienced a year-over-year decrease of 46.04%.

Score

Industry at a Glance

Previous score

5.96

Change

0



Financials

7.34

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.13

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Dianthus Therapeutics Inc is 6.72, ranking 233 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -14.49, which is -128.61% below the recent high of 4.15 and -132.24% above the recent low of -33.66.

Score

Industry at a Glance

Previous score

6.72

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Dianthus Therapeutics Inc is 8.93, ranking 37 out of 392 in the Biotechnology & Medical Research industry. The average price target is 65.00, with a high of 100.00 and a low of 46.00.

Score

Industry at a Glance

Previous score

8.93

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Dianthus Therapeutics Inc is 9.27, ranking 24 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 59.93 and the support level at 39.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.57

Change

1.7

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Dianthus Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 100.64%, representing a quarter-over-quarter decrease of 3.91%. The largest institutional shareholder is The Vanguard, holding a total of 2.04M shares, representing 4.77% of shares outstanding, with 38.27% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

5.89M

+32.33%

RA Capital Management, LP

2.87M

--

Wellington Management Company, LLP

2.58M

+3366.88%

Octagon Capital Advisors LP

2.42M

+3.20%

Fairmount Funds Management LLC

2.14M

-35.38%

Avidity Partners Management LP

2.10M

-34.33%

The Vanguard Group, Inc.

Star Investors

1.64M

+13.56%

Point72 Asset Management, L.P.

Star Investors

2.04M

+46.64%

TCG Crossover Management, LLC

1.68M

+11.65%

Tellus Bioventures LLC

1.44M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dianthus Therapeutics Inc is 5.74, ranking 41 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.59. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Dianthus Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Dianthus Therapeutics Inc

DNTH

7.71 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment